• Yungjin Pharm posted a third-quarter 2026 operating loss of KRW 2.3 billion, versus a KRW 4 million profit a year earlier.
• Revenue rose 3.1% year over year to KRW 62.71 billion.
• Sequentially, revenue increased 1.8%, while the operating loss widened 53.3%.
• Net loss widened 138% year over year to KRW 2.78 billion.
• Nine-month operating loss reached KRW 5.55 billion, compared with a KRW 4.5 billion profit a year earlier.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Yungjin Pharm. Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261104800466), on November 04, 2026, and is solely responsible for the information contained therein.